• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, April 2, 2021


Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by The Heartland Institute referenced a study published in the December 2012 issue of The American Journal of Managed Care® (AJMC®) titled “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilization.” The study assessed the impact of the MDVIP personalized preventive care model on hospital utilization and found that MDVIP members’ utilization rates were substantially lower than those of nonmembers.

Posted on einnews.com, a press release cited an article published in an August 2017 supplement to AJMC®. The article, “Overview of Atopic Dermatitis,” noted that atopic dermatitis is a multifaceted, chronic relapsing inflammatory skin disease that is the most common skin disease in children, affecting approximately 15% to 20% of children and 1% to 3% of adults.

A piece by pharmiweb.com spotlighted an article published on AJMC.com, the website of AJMC®. The article, “ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit,” noted that while the CAR-T cell therapies isagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may be high in price, a report by ICER finds that the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life-year.

Related Videos
Dr Guru Sonpavde
Video 2 - "Adverse Events & Existing Treatment Options for Dry Eye Disease"
Overview of Dry Eye Disease (DED) Causes and Treatments
Related Content
© 2023 MJH Life Sciences
All rights reserved.